The age distribution of patients by each decade is illustrated in Fig 1b. 399 (10.4%) were 18 years). A sample for karyotyping was sent in 2609 (68%).

Noted that 1766 (46%) received definitive treatment (Fig 1 a). The median age of the patients was 40 years (range: 0-89) and there were 59% males.

A total of 3848 were confirmed to have had a diagnosis of AML in this period of which it was contributed data to the data management center. A central online data capture and management system was in place which was independent of all the participating centers (Clinical Data Management Center [CDMC], Vellore, which is compliant with standard ICH-GCP regulations). In this initial phase some centers available only from January 2017).

Retrospective data from January 2013 to December 2017 was collected from 10 large tertiary centers from across the country (in one center data was available only from January 2017). A central online data capture and management system was in place which was independent of all the participating centers (Clinical Data Management Center [CDMC], Vellore, which is compliant with standard ICH-GCP regulations). In this initial phase some centers contributed data offline to the data management center. A total of 3848 were confirmed to have had a diagnosis of AML in this period of which it was noted that 1766 (46%) received definitive treatment (Fig 1 a). The median age of the patients was 40 years (range: 0–89) and there were 59% males.

**4006 Hematological Cancer Consortium: Multi-Center Acute Myeloid Leukemia Registry Data from India**

**Program: Oral and Poster Abstracts**

**Session: 613. Acute Myeloid Leukemia: Clinical Studies: Poster III**

**Hematology Disease Topics & Pathways:**

- Diseases, AML, Adult, Therapies, Non-Biological, Elderly, chemotherapy, Pediatric, Technology and Procedures, cytogenetics, Study Population,
- Clinically relevant, Myeloid Malignancies, Quality Improvement , molecular testing

**Monday, December 3, 2018, 6:00 PM-8:00 PM**

Hall GH (San Diego Convention Center)

Rajan Kapoor, MD, DM¹, Hasmukh Jain, MD, DM¹, Anu Korula, MD, DM³, Dinesh Bhurani, MD, DM, FRCPA⁴, Venkatraman Radhakrishnan, MD, DM³, Chepsy C Philip, MD⁵, Jina Bhattacharyya, MD⁶, Maitreyee Bhattacharyya, DM⁸, Smita Kayal, MD⁹, Pankaj Malhotra, MD¹⁰, Govind Babu, MD, DM¹¹, Lalit Kumar, MD DM¹², Om Prakash, MSc¹³, Ambily Nadaraj, MSc¹³, Jeyaseelan Lakshmanan, PhD¹³, Biju George, DM³, Poornkuzhali Balasubramanian, MSc³, Bhasaheb Bagal, MD, DM², Satyaranjan Das, MD¹, Rayaz Ahmed, MD, DM⁴, Prasanth Ganesan, MD, DM⁹, Gaurav Prakash, MD, DM¹⁰, Nikita Mehra, MD, DM⁵, **Manju Sengar, MD, DM²** and Vikram Mathews, MD¹⁴

¹Department of Haematology, Army Hospital R&R, New Delhi, India

²Adult hematolymphoid disease management group, Department of Medical Oncology, Tata Memorial Centre, Mumbai, India

³Department of Haematology, Christian Medical College, Vellore, India

⁴Department of Hemato-Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India

⁵Department of Medical Oncology, Cancer Institute (WIA), Chennai, India

⁶Department of Clinical Haematology, Christian Medical College & Hospital, Ludhiana, India

⁷Department of Clinical Hematology, Guwahati Medical College & Hospital, Guwahati, India

⁸Institute of Haematology &Transfusion Medicine (IHTM), Kolkata, India

⁹Department of Medical Oncology, Regional Cancer Center, Jawaharlal Institute of Postgraduate Medical Education & Research (JIPMER), Pondicherry, India

¹⁰Department of Internal Medicine and Hematology, Postgraduate Institute of Medical Education and Research, Chandigarh, India

¹¹Department of Medical Oncology, Kidwai Cancer Institute, Bangalore, India

¹²Department of Medical Oncology, Institute of Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India

¹³Department of Biostatistics, Christian Medical College, Vellore, India

¹⁴Department of Haematology, Christian Medical College, Vellore, Tamil Nadu, India

Multicenter large collaborative research groups have been the cornerstone for advances that have been made in multiple disciplines in medicine. These collaborative groups are specifically useful in situation where no single center based dataset is large enough to effectively address biological and clinically relevant questions that could advance the field. Most such collaborative groups exist in the developed countries and have contributed significantly to the development of the current standards of care in leukemia. The challenges in the developing countries or low middle income countries (LMIC) are distinctly different and often algorithms that have evolved in the developed world may not be applicable, relevant or accessible in the LMIC. It is imperative that these challenges be addressed through large multicenter studies that are located within the LMIC and appropriate local data driven solutions be implemented in response. The ‘Hematological Cancer Consortium’ is a collaborative group from India currently compromising twelve institutions spread across the country that have come together to collaborate in the field of leukemia. As an initial exercise, to establish denominators a retrospective data analysis was undertaken (Indian acute leukemia research database [INwARD]). Here we present the retrospective analysis of the acute myeloid leukemia (AML) data.
The age distribution of patients by each decade is illustrated in Fig 1b. 399 (10.4%) were ≤ 18 years). A sample for karyotyping was sent in 2609 (68%) however of these an evaluable karyotype was noted in only 1477 (57%) (Fig 1c), the reasons for lack of evaluable metaphases was not clear. A FLT3 and NPM1 mutation status was evaluated in 1338 (35%) and 1401 (36%) respectively. Of the evaluated patients 20.6% and 21.9% had FLT3-ITD and NPM1 mutated respectively (Fig 1d). Of the 1766 patients that were treated 858 (48.6%) received a conventional 7/3 induction, 170 (9.6%) received hypomethylating agents while the rest received various abbreviated dose regimens and a small proportion (2.8%) received high dose cytosine based regimens as induction therapy. Antifungal prophylaxis was used by 82% of patients that received therapy. Of those that received induction therapy there were 18% induction deaths and 12.9% subsequently received an allogeneic SCT as part of their consolidation therapy (Fig 1a). The 5 year KM estimate for overall and event free survival for the patient that received treatment was 56.2±2.6% and 33.8±2.4% respectively. The data illustrates significant challenges and opportunities with the management of AML in India. A significant proportion of cases do not receive definitive therapy nor do they have conventional tests such as karyotyping or molecular tests done as part of the baseline diagnostic tests, various social and financial constraints could contribute to these and these need to be evaluated in more detail. Strategies to increase access to care and laboratory facilities along with an effort to reduce early induction deaths need relatively urgent attention. The relatively young age of the cohort and large number of cases would allow us to address relevant biological and clinically challenges effectively, in the future, in this cooperative setting.

Figure 1: (a) Illustrate the proportion of patients treated of those diagnosed and also the proportion of those treated that had an induction death and those that received an allogeneic SCT (b) Age distribution of this cohort (c) Illustrates the proportion of cases where a karyotype was requested and the numbers in which it could be evaluated (d) Proportion of cases that were evaluated for FLT3 and NPM1 mutations and the numbers that had mutations (e) Distribution of different induction regimens that were administered to those that did receive treatment.

Disclosures: No relevant conflicts of interest to declare.

See more of: 613. Acute Myeloid Leukemia: Clinical Studies: Poster III
See more of: Oral and Poster Abstracts
<< Previous Abstract | Next Abstract >>

*signifies non-member of ASH